Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Virginie, Nerich"'
Publikováno v:
BMC Women's Health, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Breast cancer (BC) is a major health concern in Lebanon, with an increasing incidence rate due to advancements in treatment modalities. Evaluating the impact of the BC and its treatment on a woman's Health-Related Quality of Life (HRQoL), an
Externí odkaz:
https://doaj.org/article/4e01b062e85f489e94b4287bba5b1e52
Autor:
Astrid Pozet, Sophie Darnis, Magalie Bonnet, Aurélia Meurisse, Tienhan Sandrine Dabakuyo-Yonli, Catherine Lejeune, Philippe Fagnoni, Maryse Gaimard, Patrick Manckoundia, Clémence Quibel, Mélanie Marchand, Amélie Anota, Virginie Nerich
Publikováno v:
International Journal of Public Health, Vol 68 (2023)
Objectives: To assess health-related quality of life (QoL) in caregivers of elderly patients with chronic disabilities receiving, or not receiving, social worker support.Methods: This multicenter open-label randomized study assigned caregivers to rec
Externí odkaz:
https://doaj.org/article/18f0bd893afa48028483948207bcc836
Autor:
Elsa Curtit, Martine Marie Bellanger, Virginie Nerich, Delphine Hequet, Jean-Sebastien Frenel, Olivier Cristeau, Roman Rouzier
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionChemotherapy (CT) is commonly used as an adjuvant treatment for women with early breast cancer (BC). However, not all patients benefit from CT, while all are exposed to its short- and long-term toxicity. The Oncotype DX® test assesses ca
Externí odkaz:
https://doaj.org/article/c87ffa5b5cd743ce8a6acba397bb5d2c
Autor:
Margaux Damerval, Christine Fagnoni-Legat, Aurélien Louvrier, Sarah Fischer, Samuel Limat, Anne-Laure Clairet, Virginie Nerich, Isabelle Madelaine, Marie Kroemer
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Since 2007, a new class of biologic products for human use called “advanced therapy medicinal products (ATMP)” have been legally integrated in the European Medical Agency. They consist of recombinant nucleic acid, engineered cells, cells, or tiss
Externí odkaz:
https://doaj.org/article/18cd314a34e54014821d82dea62b4681
Publikováno v:
JMIR Research Protocols, Vol 10, Iss 11, p e27893 (2021)
BackgroundIn the past few decades, Lebanon has witnessed a significant increase in the incidence rates of women diagnosed with breast cancer. This increase, which is associated with the advancements in treatment modalities, emphasizes the need to eva
Externí odkaz:
https://doaj.org/article/71819b5339aa4406a83be12a7bffa7df
Publikováno v:
Actualités Pharmaceutiques. 62:44-48
Autor:
Rémi Pelloux-Prayer, Thomas Bataillard, Antoine Thiery-Vuillemin, Alexandre Vincent, Philippe Fagnoni, Virginie Nerich
Publikováno v:
Clinical Genitourinary Cancer. 20:594-602
The management of patients with metastatic hormone-sensitive prostate cancer (mHSPC) has been significantly modified by the availability of innovative but expensive treatments, increasing the economic burden of prostate cancer. Here, we aimed to syst
Autor:
Rana El Haidari, Amelie Anota, Tienhan S. Dabakuyo-Yonli, Francis Guillemin, Thierry Conroy, Michel Velten, Damien Jolly, Sylvain Causeret, Jean Cuisenier, Olivier Graesslin, Linda Abou Abbas, Virginie Nerich
Publikováno v:
Quality of Life Research. 31:3077-3085
The potential effects of breast cancer (BC) on health-related quality of life (HRQoL) should be considered in clinical and policy decision-making, as the economic burden of BC management is currently assessed. In the last decades, time-to-HRQoL score
Autor:
Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Kim, Virginie Nerich
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2016, Iss 10, Pp 59-66 (2016)
Externí odkaz:
https://doaj.org/article/4d40783b7b7d481485ea32e0c8ca7816
Autor:
Loïc Chaigneau, Marine Jary, Virginie Nerich, Alice Hervieu, Sébastien Aubry, Céline Charon Barra, Guillaume Meynard, Florent Neumann, Elsa Kalbacher, Nicolas Isambert
Publikováno v:
Oncology. 100:633-644
Introduction: Soft tissue sarcomas (STSs) are a rare and heterogenous group of tumors, with poor prognostic, judging from their frequency to relapse. Few drugs are available after the conventional first-line regimen. Since 2007, trabectedin got appro